Financial Efficiency Analysis of uniQure N.V. and Its Competitors in the Biotech Sector

uniQure N.V. (NASDAQ:QURE) has a Return on Invested Capital (ROIC) of -23.80% and a Weighted Average Cost of Capital (WACC) of 11.72%, indicating it generates returns below its cost of capital.REGENXBIO Inc. and Voyager Therapeutics, Inc. show even lower efficiency in generating returns over their cost of capital compared to uniQure.Blueprint Medicines Corporation exhibits the highest potential for improvement among the peers, with a ROIC to WACC ratio closest to breaking even.uniQure N.V. (NASDAQ:QURE) is ...